Skip to main content
. 2021 Oct 10;13(1):88–95. doi: 10.34172/apb.2023.007

Table 1. Selected studies on pembrolizumab for the treatment of NSCLC .

Study Doses Therapy design Study design Tumor Specification Ref.
KEYNOTE-001 2 mg or 10 mg/kg/3 weeks Monotherapy Clinical trial NSCLC, previously treated and untreated 16
KEYNOTE-010 2 mg or 10 mg/kg/3 weeks Monotherapy X
Docetaxel		 Randomized study Advanced NSCLC previously treated 17
KEYNOTE-024 200 mg/3 weeks Monotherapy
X
Platinum-based chemotherapy		 Randomized open study Previously untreated advanced NSCLC, PD-L1 TPS ≥ 50% 18
KEYNOTE-189 200 mg/3 weeks Pembrolizumab plus chemotherapy Double-blind clinical trial Previously Untreated Non-Squamous Metastatic NSCLC 19
KEYNOTE-407 200 mg/3 weeks Pembrolizumab plus chemotherapy Double-blind clinical trial Previously untreated metastatic squamous NSCLC 20
KEYNOTE-042 200 mg/3 weeks Monotherapy
X
Platinum-based chemotherapy		 Randomized open study Previously Untreated NSCLC PD-L1 TPS ≥ 1% 21
Subgroup KEYNOTE-024 Japan 200 mg/3 weeks Monotherapy
X
Platinum-based chemotherapy		 Randomized open study Previously untreated metastatic NSCLC PD-L1 TPS ≥ 50% 22